Reply to A Discussion of 2 Double-Blind Studies Comparing Risperidone and Quetiapine in Patients With Schizophrenia

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Dr. Gharabawi’s recent letter regarding the trials conducted by Potkin et al.1 and Zhong et al.2 highlights several salient points on the interpretation of data from comparative studies. Questions were raised about the trial designs that merit a response in the wider context of ongoing research on atypicalantipsychotic efficacy and safety.

Gharabawi and colleagues comment on several aspects of the methodology of the trial by Zhong et al.,2 primarily in an attempt to account for the nonsignificant difference between quetiapine and risperidone for the primary endpoint (PANSS total score).’ ‹’ ‹